Esperion Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 137.74 million compared to USD 24.33 million a year ago. Net income was USD 61.02 million compared to net loss of USD 61.72 million a year ago.

Basic earnings per share from continuing operations was USD 0.36 compared to basic loss per share from continuing operations of USD 0.79 a year ago. Diluted earnings per share from continuing operations was USD 0.34 compared to diluted loss per share from continuing operations of USD 0.79 a year ago.